Serological tests for SARS-CoV-2, while not intended as a primary diagnostic tool for COVID-19, are used to detect antibodies to the SARS-CoV-2 virus. These antibodies are produced following activation of the body’s adaptive immune response. This process is triggered after viral exposure and results in the virus’s destruction and subsequent elimination from the body. At this time, it is not known whether these antibodies provide immunity; however, SARS-CoV-2 serological tests may aid in recognizing high-risk populations, enhancing our understanding of the virus’ epidemiology and identifying individuals with past asymptomatic infections
Dominion Diagnostics utilizes the Siemens SARS-CoV-2 Total Antibody test to identify two antibodies, Immunoglobulin M (IgM) and Immunoglobulin G (IgG). Both antibodies are produced by the immune system in response to SARS-CoV-2, the virus strain that causes the disease COVID-19. IgM is produced during the initial immune response and can be detected as early as several days after infection. This antibody is relatively short-lived, remaining in the body for 3 to 4 weeks. The second antibody, IgG, is produced in greater quantities and begins to appear shortly after IgM. The IgG antibodies may serve as the basis for long-term immunity, possibly conferring resistance for months or years.
Specimen: 1 mL serum in a Serum Separator Tube/SST (0.5 mL min)
Stability: 2 days (Refrigerated)
Results Within: 2 - 3 days
The SARS-CoV-2 Total Antibody test provides qualitative results (Detected/Not Detected) and does not currently have an antibody titer (i.e. quantitative assessment of the amount of antibodies present).
This test has not been reviewed by the FDA but is being offered by Dominion Diagnostics under FDA Emergency Use Authorization.
Our self-pay rate is $75.
If you are interested in Serology Antibody Testing, please contact your local representative, or call (800) 511-8427